Medtech giant Abbott Laboratories Inc. and San Francisco-based digital health company Omada Health announced a partnership to give type 2 diabetes patients who use Abbott's FreeStyle Libre access to Omada's coaching and chronic disease management platform.
This move could potentially widen the user base of Abbott's continuous glucose monitoring system through
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?